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Abstract
Background: Hypokalemia and acute kidney injury (AKI) occur in patients administered liposomal amphotericin B
(L-AMB), a wide-spectrum anti-fungicidal drug. However, the association between potassium supplementation and
the occurrence of AKI in patients with hypokalemia who were administered L-AMB is not well understood.
Methods: Using nationwide claims data and laboratory data, the occurrence of AKI during L-AMB treatment was
retrospectively compared between patients with hypokalemia who were or were not supplemented with
potassium and between those adequately or inadequately supplemented with potassium (serum potassium levels
corrected to ≥3.5 mEq/L or remained < 3.5 mEq/L, respectively) before or after L-AMB treatment initiation.
Results: We identified 118 patients who developed hypokalemia before L-AMB treatment initiation (43 received
potassium supplementation [25 adequate and 18 inadequate supplementation] and 75 did not receive potassium
supplementation), and 117 patients who developed hypokalemia after L-AMB initiation (79 received potassium
supplementation [including 23 adequate and 15 inadequate supplementation] and 38 did not receive potassium
supplementation). The occurrence of any stage of AKI was similar between patients with hypokalemia, regardless of
potassium supplementation (i.e., before L-AMB treatment initiation [supplementation, 51%; non-supplementation,
45%; P = 0.570] or after L-AMB initiation [supplementation, 28%; non-supplementation, 32%; P = 0.671]). After
adjusting for confounding factors, we found that the occurrence of any stage of AKI was not associated with
potassium supplementation before L-AMB initiation (odds ratio [OR]: 1.291, 95% confidence interval [CI]: 0.584–
2.852, P = 0.528) or after L-AMB initiation (OR: 0.954, 95% CI: 0.400–2.275, P = 0.915). The occurrence of any stage of
AKI tended to decline in patients with hypokalemia who were adequately supplemented with potassium (44%)
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before, but not after, L-AMB initiation relative to that in patients inadequately supplemented with potassium (61%),
however this result was not significant (P = 0.358).
Conclusion: Potassium supplementation was not associated with any stage of AKI in patients with hypokalemia
who were administered L-AMB.
Keywords: Liposomal amphotericin B, Hypokalemia, Potassium supplementation, Acute kidney injury, Observational
study
Background
Invasive fungal infections frequently occur in immuno-
compromised and critically ill patients and are associated
with high morbidity and mortality [1, 2]. Amphotericin B
(AMB) is a broad-spectrum anti-fungicidal drug that is
used against yeasts and molds that cause mycoses, such as
aspergillosis, candidiasis, cryptococcosis, and mucormyco-
sis [3]. However, the high occurrence of toxicity associated
with AMB, including nephrotoxicity, liver disorder, or
hypokalemia, has limited its use [3, 4]. Liposomal ampho-
tericin B (L-AMB), which contains AMB encapsulated in
a lipid membrane, was developed to reduce AMB toxicity,
without reducing its antifungal activity [3, 5]. However, re-
gardless of its reduced nephrotoxicity, physicians are re-
luctant to prescribe L-AMB owing to its association with
the occurrence of renal dysfunction or hypokalemia [6].
L-AMB may induce nephrotoxicity through tubular in-
jury or renal vasoconstriction [7, 8]. Tubular injury may
be induced by intramembranous pore formation or
vacuolation of the epithelial cells in the distal convoluted
tubule [9], while vasoconstriction may be induced by dir-
ect vasoconstrictor effects that might be initiated by the
depolarization-induced opening of calcium channels
[10]. This tubular injury may, in part, be responsible for
L-AMB-induced hypokalemia [9]. Tubular injury may
lead to increased permeability of the distal convoluted
tubule and a subsequent increase in urinary potassium
secretion through tubular Na+, K+-ATPase [9]. In
addition, tubular injury may result in a defective the dis-
tal tubule H+, K+-ATPase, or renal tubular acidosis,
causing increased potassium elimination [9].
Hypokalemia, especially if persistent, is associated with
renal dysfunction, such as degeneration of the convo-
luted tubules [11]. This degeneration may be caused by
tubular cytoplasmic vacuolization, cyst formation and
interstitial fibrosis [12, 13]. Additionally, short-term
hypokalemia developed before L-AMB initiation is an in-
dependent risk factor for severe acute kidney injury
(AKI) stage 2 or 3 during L-AMB treatment [14]. Thus,
intervention for hypokalemia in patients administered L-
AMB could be essential to prevent AKI progression.
Several studies conducted in single facilities showed
that potassium supplementation helps prevent hypokal-
emia during L-AMB treatment [15, 16]. However,
association between potassium supplementation and the
occurrence of AKI in patients with hypokalemia admin-
istered L-AMB has not been well understood. Using na-
tionwide claims data for Japan and laboratory data, we
aimed to evaluate the association between potassium
supplementation and the occurrence of AKI develop-
ment during L-AMB treatment in patients with hypokal-
emia, which developed before or after L-AMB treatment
initiation. We compared AKI occurrence during L-AMB
treatment between patients with hypokalemia who were
or were not supplemented with potassium as well as be-
tween patients who were adequately or inadequately




This retrospective, multicenter, observational study was
based on data retrieved between April 2008 and January
2018 from an electronic medical information database
(Medical Data Vision Co., Ltd.) [14]. This database con-
tains diagnosis procedure combination hospital data,
medical fee reimbursement claims, and clinical labora-
tory test data from 345 facilities in Japan. The database
included information regarding age, sex, diagnosis, and
comorbidities at admission, coded using the Inter-
national Classification of Diseases, 10th Revision codes.
The database also contained dosages and administration
dates of drugs as well as interventional procedures dur-
ing hospitalization. Subjects were admitted to public,
private, or government hospitals, but not university hos-
pitals or facilities that had less than 200 beds.
Study design
As described by Takazono et al. [14], we identified 507
subjects administered L-AMB during hospitalization.
Thereafter, two study populations were independently
selected. First, patients who developed hypokalemia be-
fore L-AMB treatment initiation were identified as sub-
jects with serum potassium levels < 3.5 mEq/L between 7
and 2 days before L-AMB initiation. Among these, sub-
jects supplemented with potassium were defined as pa-
tients treated with potassium L-aspartate, potassium
gluconate, or potassium chloride between the day after
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hypokalemia onset and the day before the most recent
date of potassium measurement until L-AMB initiation.
Subjects supplemented with potassium were divided into
those with adequate supplementation defined as a cor-
rection of the serum potassium levels to ≥3.5 mEq/L on
the most recent date of potassium measurement until L-
AMB initiation and those with inadequate supplementa-
tion defined as incomplete serum potassium correction
(i.e., < 3.5 mEq/L). Second, patients who developed hypo-
kalemia after L-AMB initiation were identified as sub-
jects who met the following criteria: 1) serum potassium
levels ≥3.5 mEq/L on the most recent date of potassium
measurement until L-AMB initiation, and 2) serum po-
tassium levels < 3.5 mEq/L between the day after L-AMB
initiation and 2 days before the onset of AKI or the day
before L-AMB termination. Among these, subjects sup-
plemented with potassium were defined as patients
treated with potassium between the day after hypokal-
emia onset and the day before AKI onset or the day of
L-AMB termination. Further, to evaluate AKI, we se-
lected patients who had either serum creatinine levels
measured or underwent dialysis between the day after
potassium supplementation initiation (supplementation
group) or 2 days after hypokalemia onset (non-supple-
mentation group) and 7 days after L-AMB termination.
To assess the association between the adequacy of potas-
sium supplementation and AKI, we selected patients
who had received potassium supplementation and had
their serum potassium levels measured between the day
after supplementation termination and the day before
AKI onset or 6 days after L-AMB termination. Adequate
potassium supplementation was defined as the correc-
tion of serum potassium levels to ≥3.5 mEq/L on the day
of serum potassium measurement immediately after the
day of potassium supplementation termination, while in-
adequate potassium supplementation was defined as in-
complete serum potassium correction (< 3.5 mEq/L).
Further, to evaluate AKI, we assessed patients who had
either serum creatinine levels measured or underwent
dialysis between the day after the day of adequacy judge-
ment was made (i.e. adequate or inadequate supplemen-
tation with potassium) and 7 days after L-AMB
termination.
Assessments
AKI and estimated glomerular filtration rate (eGFR)
were defined as described by Takazono et al. [14].
Briefly, based on the KDIGO AKI criteria, AKI was de-
fined as a ≥ 1.5-fold increase within 7 days or ≥ 0.3 mg/
dL increase within 2 days in serum creatinine (Cr) levels.
AKI patients were assigned to either of three stages:
stage 1, ≥1.5- to < 2-fold increase or ≥ 0.3 mg/dL increase
in Cr; stage 2, ≥2- to < 3-fold increase in Cr; stage 3, ≥3-
fold increase in Cr, ≥4.0 mg/dL of Cr or dialysis
initiation. eGFR was calculated with the following for-
mula for Japanese individuals:
eGFR mL= minð Þ ¼ ½194 Cr concentration mg=dLð Þ - 1:094
age yearsð Þ - 0:287 0:739 for womenð Þ=1:73 m2
Body surface area m2 
Body surface area m2
  ¼ 0:007184
 weight kgð Þ½ 0:425
 height cmð Þ½ 0:725
To calculate eGFR at baseline, the minimum level of
Cr measured between 180 and 7 days before L-AMB ini-
tiation was used.
Sex and age were obtained on the first day of the
month of L-AMB initiation. Comorbidities and fungal
infections were identified using the corresponding ICD-
10 codes which were registered on the month of L-AMB
initiation. L-AMB treatment duration was defined as the
time from treatment initiation to discontinuation (inter-
val ≥ 8 days). The treatment department was defined as
that which initiated L-AMB treatment.
Variables associated with serum potassium levels and
potassium supplementation were assessed at different
periods between patients with hypokalemia before and
after L-AMB initiation. The duration of hypokalemia
was defined as the consecutive duration of having a
serum potassium level < 3.5 mEq/L between 7 days be-
fore and the day of L-AMB initiation for patients with
hypokalemia before L-AMB initiation, while that was
also defined as the consecutive duration of having a
serum potassium level < 3.5 mEq/L between the day after
L-AMB initiation and the day before AKI or 7 days after
L-AMB termination for patients with hypokalemia after
L-AMB initiation. For patients with hypokalemia before
L-AMB initiation, the minimum level of serum potas-
sium was evaluated between 7 days before and the day of
L-AMB initiation for patients who were or were not sup-
plemented with potassium or between 7 days before L-
AMB initiation and the day before supplementation ini-
tiation for patients who were adequately or inadequately
supplemented with potassium. For patients with hypo-
kalemia after L-AMB initiation, the minimum serum
potassium level was also evaluated between the day after
L-AMB initiation and the day before AKI or 7 days after
L-AMB termination for patients who were or were not
supplemented with potassium or between the day after
L-AMB initiation and the day before potassium supple-
mentation initiation for patients who were adequately or
inadequately supplemented with potassium. The average
serum potassium levels and the duration of potassium
supplementation following hypokalemia onset, defined
as the time from supplementation initiation to discon-
tinuation (interval ≥ 2 days), were evaluated between 7
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days before and the day of L-AMB initiation for patients
with hypokalemia before L-AMB initiation, or between
the day after L-AMB initiation and the day before AKI
or 7 days after L-AMB termination for patients with
hypokalemia after L-AMB initiation. Daily and cumula-
tive potassium dosing during potassium supplementa-
tion duration were also calculated.
We identified drug treatments during the different pe-
riods based on the types of drugs or subjects. Pretreat-
ment with potassium-related drugs was identified
between 7 days before and the day of L-AMB initiation.
However, only for patients who were adequately or inad-
equately supplemented with potassium before L-AMB
initiation, pretreatment with potassium-related drugs
was identified between 7 days before L-AMB initiation
and the most recent potassium measurement until L-
AMB initiation. Concomitant treatment with potassium-
related drugs was identified between the day after L-
AMB initiation and the day before AKI or 7 days after L-
AMB termination. However, only for patients who were
adequately or inadequately supplemented with potas-
sium after L-AMB initiation, concomitant treatment
with potassium-related drugs was identified between the
day after L-AMB initiation and the day of serum potas-
sium measurement immediately following the day of po-
tassium supplementation termination. Pretreatment with
AKI-related drugs was identified between the admission
date and the day before L-AMB initiation, while con-
comitant treatment with AKI-related drugs was identi-
fied between the day of L-AMB initiation and
termination.
Statistical analysis
The occurrence of AKI (any or each stage) during L-
AMB treatment was compared between patients with
hypokalemia who were or were not supplemented with
potassium or between those adequately or inadequately
supplemented with potassium before or after L-AMB
initiation using the Fisher’s exact test. To exclude the ef-
fect of the confounding factors on renal dysfunction, lo-
gistic regression analysis was conducted using the
occurrence of AKI (any stage, stage 2 or 3, or stage 2 or
3 excluding dialysis) as the dependent variable. We have
selected 13 independent variables associated with AKI in
patients who developed hypokalemia and were adminis-
tered L-AMB. These variables included those related to
potassium supplementation, age, sex, comorbidities (dia-
betes mellitus, hypertension, heart failure), severe infection
(defined as treatment with catecholamine), baseline eGFR,
L-AMB cumulative dosing, minimum serum potassium
levels, and treatment with AKI-related drugs (angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker
[ACE inhibitors/ARB], loop/thiazide diuretic drugs, or im-
munosuppressant/steroid). For logistic regression analysis,
minimum serum potassium and treatment with drugs were
evaluated between 7 days before L-AMB initiation and the
day before AKI or 7 days after L-AMB termination. The
variables were subjected to univariate binomial logistic re-
gression analysis. Potassium supplementation and variables
with a P-value of < 0.2 in univariate logistic regression ana-
lysis were subjected to multivariate logistic regression ana-
lysis. Continuous variables (L-AMB cumulative dosing or
minimum serum potassium levels) were divided into two
groups using the cut-off value calculated with receiver op-
erating characteristic curves when analyzed with the multi-
variate logistic regression model. The association between
adequate potassium supplementation and sex was evaluated
using univariate logistic regression analysis with adequate
or inadequate potassium supplementation as the dependent
variable and with sex as the independent variable in pa-
tients with hypokalemia who were supplemented with po-
tassium before L-AMB initiation. The association between
drug treatments and AKI was evaluated using univariate lo-
gistic regression analysis with any stage of AKI as the
dependent variable and drug treatments as the independent
variable in patients with hypokalemia who were or were
not supplemented with potassium before L-AMB initiation.
Odds ratio (OR), 95% confidence interval (CI) and variance
inflation factor (VIF) were calculated. To evaluate patient
characteristics, the Welch’s t-test was used to compare the
two groups for continuous variables, while the Fisher’s
exact test was used for two categorical variables.
Results
Study population
As shown in Fig. 1, by applying the criteria and defini-
tions described in the Materials and Methods, we identi-
fied 118 patients who developed hypokalemia before L-
AMB treatment initiation (43 received potassium sup-
plementation and 75 did not receive potassium supple-
mentation). Of the 43 patients who were supplemented
with potassium, 25 received adequate supplementation
and 18 received inadequate supplementation. Addition-
ally, 117 patients who developed hypokalemia after L-
AMB initiation were identified: 79 received potassium
supplementation and 38 did not receive potassium sup-
plementation. Of the 79 patients, 23 received adequate
supplementation with potassium while 15 received inad-
equate supplementation with potassium.
Association between potassium supplementation and AKI
occurrence in patients with hypokalemia and
administered L-AMB
The characteristics of patients with hypokalemia who
were or were not supplemented with potassium before
or after L-AMB treatment are presented in Table 1. In
patients who developed hypokalemia before L-AMB
treatment initiation, the minimum serum potassium
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levels and potassium levels upon hypokalemia onset
were lower in patients supplemented with potassium be-
fore L-AMB initiation than in patients who did not re-
ceive potassium supplementation. The proportion of
patients treated with potassium-sparing diuretic agents
until L-AMB initiation was higher in patients supple-
mented with potassium than in patients who did not re-
ceive potassium supplementation. The occurrence of any
stage of AKI was comparable between both populations
(supplementation 22/43, 51%; non-supplementation 34/
75, 45%; P = 0.570) (Table 2). To exclude the effect of
the confounding factors on renal dysfunction, we con-
ducted logistic regression analysis. Through univariate
logistic regression analysis, four variables were associated
with any stage of AKI (P < 0.2) (< 65 years of age, hyper-
tension, higher minimum serum potassium level, and
treatment with ACE inhibitors/ARB) (Table 3). Using
these variables and potassium supplementation in multi-
variate regression analysis, we found that potassium sup-
plementation before L-AMB initiation was not
Fig. 1 Flow chart for patient selection. K: potassium; L-AMB: liposomal-amphotericin B; suppl.: supplementation
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associated with any stage of AKI (OR: 1.291, 95% CI:
0.584–2.852, P = 0.528) (Table 3). Moreover, potassium
supplementation before L-AMB initiation was associated
with neither AKI stage 2 or 3 (OR: 0.902, 95% CI:
0.364–2.237, P = 0.824) (Table S1) nor AKI stage 2 or 3
excluding dialysis (OR: 0.710, 95% CI: 0.274–1.845, P =
0.482) (Table S2).
Of the patients who developed hypokalemia after L-
AMB initiation, those supplemented with potassium
after L-AMB initiation had a higher prevalence of heart
failure than those who did not receive potassium supple-
mentation. Further, patients supplemented with potas-
sium received L-AMB for a longer duration (24.7 days)
than those who did not receive potassium supplementa-
tion (13.8 days). The daily and cumulative administration
doses of L-AMB were higher in patients supplemented
with potassium (2.8 ± 0.9 mg/kg/day and 68.9 ± 55.6mg/
kg, respectively) than those in patients who did not receive
potassium supplementation (2.4 ± 0.6mg/kg/day and
34.2 ± 20.7mg/kg, respectively). The minimum serum
Table 2 AKI occurrence in hypokalemic patients with or without potassium supplementation administered L-AMB
Patients who developed hypokalemia before L-AMB
treatment initiation















AKI (any stage) 56 (47%) 22 (51%) 34 (45%) 0.570 34 (29%) 22 (28%) 12 (32%) 0.671
Stage 1 25 (21%) 11 (26%) 14 (19%) 0.483 18 (15%) 12 (15%) 6 (16%) 1.000
Stage 2 or 3 31 (26%) 11 (26%) 20 (27%) 1.000 16 (14%) 10 (13%) 6 (16%) 0.775
Stage 2 22 (19%) 6 (14%) 16 (21%) 0.462 8 (7%) 6 (8%) 2 (5%) 1.000
Stage 3 9 (8%) 5 (12%) 4 (5%) 0.283 8 (7%) 4 (5%) 4 (11%) 0.435
Dialysis 2 (2%) 2 (5%) 0 (0%) 0.131 1 (1%) 1 (1%) 0 (0%) 1.000
AKI stage 1, Cr ≥1.5 to < 2-fold or ΔCr ≥0.3 mg/dL; stage 2, Cr ≥2 to < 3-fold; stage 3, Cr ≥3-fold or Cr ≥4.0 mg/dL or dialysis. Variables are presented as
frequencies and proportions (%). P-values were calculated using the Fisher’s exact test. AKI acute kidney injury, Cr creatinine, K potassium, L-AMB liposomal-
amphotericin B, suppl. supplementation
Table 3 Logistic regression analysis of the factors associated with AKI in hypokalemic patients before L-AMB initiation
Univariate regression Multivariate regression
Variables OR (95% CI) P-value OR (95% CI) P-value VIF
K suppl., with (vs without) 1.263 (0.596–2.677) 0.542 1.291 (0.584–2.852) 0.528 1.009
Age, ≥65 years (vs < 65 years) 0.439 (0.206–0.938) 0.034 0.479 (0.217–1.056) 0.068 1.015
Sex, male (vs female) 1.204 (0.574–2.522) 0.623
Comorbidities, with (vs without)
Diabetes mellitus 1.263 (0.596–2.677) 0.542
Hypertension 1.704 (0.793–3.659) 0.172 1.397 (0.617–3.163) 0.422 1.042
Heart failure 1.667 (0.708–3.924) 0.242
Severe infection (Catecholamine treatment, with [vs without]) 1.787 (0.593–5.387) 0.302
Baseline eGFR, ≥60mL/min (vs < 60 mL/min) 1.962 (0.627–6.139) 0.247
L-AMB cumulative dosing (mg/kg, continuous value) 1.001 (0.991–1.011) 0.875
Minimum K (mEq/L)
Univariate regression: continuous value 2.573 (0.889–7.449) 0.081 2.398 (1.038–5.537) 0.041 1.022
Multivariate regression: ≥2.91 mEq/L (vs < 2.91 mEq/L)
Drug treatment, with (vs without)
ACE inhibitors/ARB 2.417 (0.686–8.517) 0.170 2.063 (0.536–7.946) 0.293 1.056
Loop/thiazide diuretic drugs 0.736 (0.343–1.582) 0.433
Immunosuppressant/Steroid 0.585 (0.206–1.660) 0.314
Logistic regression analysis was conducted using the occurrence of any stage of AKI as the dependent variable. Thirteen independent variables related to AKI
were subjected to univariate binomial logistic regression analysis. K suppl. and variables with a P-value of < 0.2 in univariate logistic regression analysis were
subjected to multivariate logistic regression analysis. The continuous variable (i.e., minimum K level) was divided into two groups based on the cut-off value when
analyzed using the multivariate logistic regression model. OR, 95% CI, and VIF were calculated. AKI acute kidney injury, ACE inhibitors/ARB angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker, CI confidence interval, eGFR estimated glomerular filtration rate, K potassium, L-AMB liposomal-amphotericin B,
suppl. Supplementation, OR odds ratio, VIF variance inflation factor.
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potassium levels were lower in patients supplemented
with potassium than those in patients who did not receive
potassium supplementation. The proportion of patients
treated with potassium-sparing diuretic agents after L-
AMB initiation was higher in patients supplemented with
potassium than those who did not receive potassium sup-
plementation. The occurrence of any stage of AKI was
comparable between both populations (supplementation
22/79, 28%; non-supplementation 12/38, 32%; P = 0.671;
Table 2). We conducted logistic regression analysis to ad-
just for potential confounding variables. Through univari-
ate logistic regression analysis, treatment with loop/
thiazide diuretic drugs was identified as the factor associ-
ated with any stage of AKI (P < 0.2) (Table 4). Using this
variable and potassium supplementation in multivariate
regression analysis, we found that potassium supplemen-
tation conducted after L-AMB initiation was not associ-
ated with any stage of AKI (OR: 0.954, 95% CI: 0.400–
2.275, P = 0.915; Table 4).
Association between adequate potassium
supplementation and AKI occurrence in patients with
hypokalemia administered L-AMB
The characteristics of patients with hypokalemia who
were adequately or inadequately supplemented with po-
tassium before or after L-AMB treatment initiation are
shown in Table S3. Of the patients who developed hypo-
kalemia and received potassium supplementation before
L-AMB initiation, patients adequately supplemented
with potassium had a lower prevalence of heart failure
and higher average concentrations of serum potassium
than those inadequately supplemented with potassium.
Patients inadequately supplemented with potassium suf-
fered from hypokalemia for a longer period than those
adequately supplemented with potassium. The occurrence
of any stage of AKI was slightly though not significantly in
patients adequately supplemented with potassium com-
pared with that in patients inadequately supplemented
with potassium (adequate: 11/25, 44%; inadequate: 11/18,
61%; P = 0.358) (Table 5). Further, after stratifying subjects
according to their characteristics, we found that female
adequately supplemented with potassium had a lower oc-
currence of AKI stage 2 or 3 than females inadequately
supplemented with potassium (adequate: 0/7, 0%; inad-
equate: 5/9, 56%; P = 0.034; Table S4).
Table S3 shows that among patients who developed
hypokalemia and received potassium supplementation
after L-AMB initiation, those adequately supplemented
with potassium were older and had lower eGFR than
those inadequately supplemented with potassium. Pa-
tients inadequately supplemented with potassium suf-
fered from hypokalemia for a longer period than those
adequately supplemented with potassium. The average
concentration of serum potassium was higher in patients
adequately supplemented with potassium than that in
patients inadequately supplemented with potassium.
Table 4 Logistic regression analysis of the factors associated with AKI in hypokalemic patients after L-AMB initiation
Univariate regression Multivariate regression
Variables OR (95% CI) P-value OR (95% CI) P-value VIF
K suppl., with (vs without) 0.836 (0.360–1.942) 0.677 0.954 (0.400–2.275) 0.915 1.046
Age, ≥65 years (vs < 65 years) 0.884 (0.382–2.048) 0.773
Sex, male (vs female) 1.337 (0.584–3.058) 0.492
Comorbidities, with (vs without)
Diabetes mellitus 0.747 (0.307–1.817) 0.520
Hypertension 0.869 (0.379–1.995) 0.741
Heart failure 0.657 (0.200–2.162) 0.490
Severe infection (Catecholamine treatment, with [vs without]) 1.129 (0.360–3.534) 0.836
Baseline eGFR, ≥60mL/min (vs < 60 mL/min) 2.704 (0.572–12.792) 0.210
L-AMB cumulative dosing (mg/kg, continuous value) 0.994 (0.985–1.004) 0.237
Minimum K (mEq/L, continuous value) 1.662 (0.568–4.870) 0.354
Drug treatment, with (vs without)
ACE inhibitors/ARB 1.418 (0.438–4.588) 0.560
Loop/thiazide diuretic drugs 0.548 (0.245–1.227) 0.143 0.553 (0.243–1.261) 0.159 1.046
Immunosuppressant/Steroid 0.783 (0.285–2.150) 0.634
Logistic regression analysis was conducted using the occurrence of any stage of AKI as the dependent variable. Thirteen independent variables associated with
AKI were subjected to univariate binomial logistic regression analysis. K suppl. and variable with a P-value of < 0.2 in univariate logistic regression analysis were
subjected to multivariate logistic regression analysis. OR, 95% CI, and VIF were calculated. AKI acute kidney injury, ACE inhibitors/ARB angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker, CI confidence interval, eGFR estimated glomerular filtration rate, K potassium, L-AMB liposomal-amphotericin B,
suppl. Supplementation, OR odds ratio, VIF variance inflation factor.
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Further, adequately supplemented patients received po-
tassium for a longer duration and a higher cumulative
potassium dosing than the inadequately supplemented
patients. The occurrence of any stage of AKI was com-
parable between both populations (adequate: 4/23, 17%;
inadequate: 2/15, 13%; P = 1.000; Table 5).
Discussion
Herein, potassium supplementation was not associated
with the occurrence of any stage of AKI in patients with
hypokalemia and treated with L-AMB. However, we
found that patients with hypokalemia receiving adequate
potassium supplementation before L-AMB initiation had
a slightly lower occurrence of AKI compared with those
receiving inadequate potassium supplementation, al-
though this difference did not reach statistical significance.
Although the number of subjects included in this study
was limited, this tendency might be observed in patients
with severe AKI (stage 2 or 3; adequate 20% vs inadequate
33%, P = 0.480). Additionally, the occurrence of AKI stage
2 or 3 may be especially decreased in patients with severe
hypokalemia < 3.0mEq/L and adequately supplemented
with potassium (adequate 11% vs inadequate 50%, P =
0.131) or in those who initiated potassium supplementa-
tion on the day immediately after hypokalemia onset and
were adequately supplemented with potassium (adequate
16% vs inadequate 40%, P = 0.193; Table S4). A signifi-
cantly lower occurrence of AKI stage 2 or 3 was observed
in females adequately supplemented with potassium be-
fore L-AMB initiation (adequate 0% vs inadequate 56%,
P = 0.034), despite adequate potassium supplementation
before L-AMB initiation not being associated with sex
(OR 2.571, 95% CI 0.721–9.167, P = 0.145). This differ-
ence, may be, in part, owing to the less frequent use of
cytotoxic anti-cancer agents (adequate 2/7, 29% vs inad-
equate 9/9, 100%, P = 0.005) or fluoroquinolone (adequate
1/7, 14% vs inadequate 7/9, 78%; P = 0.041) in females
prior to L-AMB initiation. Notably, cytotoxic anti-cancer
agents and fluoroquinolone are known to be associated
with AKI [17, 18].
The occurrence of any stage of AKI was not associated
with potassium supplementation in patients with hypo-
kalemia administered L-AMB, which was confirmed
after adjusting for potential confounding variables. As L-
AMB treatment decreases serum potassium levels, in a
portion of the study subjects supplemented with potas-
sium, insufficient correction or maintenance failure of
serum potassium levels might lead to renal dysfunction.
Considering that potassium supplementation prior to
deterioration of hypokalemia effectively corrected
serum potassium levels in patients treated with L-
AMB [16], early potassium supplementation might be
effective for preventing AKI. For patients treated with
L-AMB, appropriate timing for potassium supplemen-
tation after hypokalemia onset, proper dosing or dur-
ation of potassium supplementation, as well as the
potential effects on renal dysfunction must be further
elucidated.
Before applying the criteria of patient selection for AKI
evaluation, we observed that 43% (122/282) of the patients
developed hypokalemia (< 3.5 mEq/L serum potassium)
after L-AMB initiation, which agreed with the value re-
ported in another study [19]. In patients who developed
hypokalemia after L-AMB initiation, the time from hypo-
kalemia onset to AKI onset tended to be longer in patients
supplemented with potassium than in those who did not
receive potassium supplementation (supplementation:
11.0 ± 10.6 days, non-supplementation: 6.3 ± 3.7 days, P =
0.073). The time from L-AMB initiation to hypokalemia
onset was similar between both populations (supplemen-
tation: 4.1 ± 2.4 days, non-supplementation: 4.6 ± 4.2 days,
P = 0.724). Potassium supplementation was promptly per-
formed within 1.5 ± 1.3 days after hypokalemia onset.
Thus, potassium supplementation might be effective at
delaying AKI development in patients who develop hypo-
kalemia after L-AMB initiation.
Table 5 AKI occurrence in hypokalemic patients adequately or inadequately supplemented with potassium administered L-AMB
Patients who developed hypokalemia before L-AMB
treatment initiation











AKI (any stage) 11 (44%) 11 (61%) 0.358 4 (17%) 2 (13%) 1.000
Stage 1 6 (24%) 5 (28%) 1.000 2 (9%) 1 (7%) 1.000
Stage 2 or 3 5 (20%) 6 (33%) 0.480 2 (9%) 1 (7%) 1.000
Stage 2 3 (12%) 3 (17%) 0.683 1 (4%) 1 (7%) 1.000
Stage 3 2 (8%) 3 (17%) 0.634 1 (4%) 0 (0%) 1.000
Dialysis 1 (4%) 1 (6%) 1.000 0 (0%) 0 (0%) 1.000
Adequate potassium supplementation was defined as the correction of serum potassium levels to ≥3.5 mEq/L, while inadequate potassium supplementation was
defined as incomplete serum potassium correction (i.e., < 3.5 mEq/L). AKI stage 1, Cr ≥1.5 to < 2-fold or ΔCr ≥0.3 mg/dL; stage 2, Cr ≥2 to < 3-fold; stage 3, Cr ≥3-
fold or Cr ≥4.0 mg/dL or dialysis. Variables are presented as frequencies and proportions (%). P-values were calculated using the Fisher’s exact test. AKI acute
kidney injury, Cr creatinine, K potassium, L-AMB liposomal-amphotericin B, suppl. supplementation.
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Among patients who developed hypokalemia after L-
AMB initiation, those supplemented with potassium had a
longer duration of L-AMB treatment than those who did
not receive potassium supplementation, thereby aligning
with a prior finding [16]. Evidently, such findings were ob-
served in patients who did not develop AKI (supplementa-
tion: 27.3 ± 18.3 days, non-supplementation: 12.3 ± 6.3
days, P < 0.001). However, in patients who developed AKI,
no remarkable difference was observed (supplementation,
18.0 ± 13.2 days; non-supplementation, 16.9 ± 8.2 days,
P = 0.777). Patients requiring long-term treatment with L-
AMB might often be supplemented with potassium.
Moreover, preventing AKI might be important to con-
tinue L-AMB treatment.
Hypokalemia that persists for at least 1 month could
be associated with vacuolar lesions in the epithelial cells
of the proximal or distal tubule [20]. Moreover, pro-
longed hypokalemia could be a risk factor for interstitial
nephritis or fibrosis, tubular atrophy, and cyst formation,
thereby causing severe renal dysfunction [20]. In patients
not prescribed potassium-wasting diuretics, a serum po-
tassium level of < 3.5 mEq/L (mmol/L) was significantly
associated with chronic kidney disease or end-stage renal
disease [21]. Therefore, < 3.5 mEq/L of hypokalemia that
persists for more than 1 month might affect renal
function.
In this study, the occurrence of any stage or stage 2 or
3 of AKI was slightly though not significantly in patients
aged ≥65 years who developed hypokalemia before L-
AMB initiation compared with that in those aged < 65
years (Table 3; S1; S2). This might be due to the less fre-
quent use of AKI-associated drugs in patients aged ≥65
years with hypokalemia before L-AMB initiation than in
those aged < 65 years. Those drug treatments included
4th generation cephalosporins before L-AMB initiation
(≥65 years: 34/73 47%, < 65 years: 32/45 71%, P = 0.013;
association with any stage of AKI, OR: 2.216, 95% CI:
1.052–4.667, P = 0.036), vancomycin before L-AMB initi-
ation (≥65 years: 26/73 36%, < 65 years: 25/45 56%, P =
0.038; association with any stage of AKI, OR:4.091 95%
CI: 1.887–8.870, P < 0.001), or immunosuppressants after
L-AMB initiation (≥65 years: 4/73 5%, < 65 years: 13/45
29%, P < 0.001; association with any stage of AKI, OR:
3.109, 95% CI: 1.020–9.481, P = 0.046). Thus, patients
aged ≥65 years with hypokalemia before L-AMB initi-
ation were less frequently treated with nephrotoxic
drugs, which might have offered protection against the
development of AKI.
This study had several limitations. First, due to its retro-
spective design, this study cannot prove a cause-effect rela-
tionship between the use of L-AMB and the development
of hypokalemia or AKI, and is therefore merely hypothesis-
generating. Second, the generalizability of the findings
should be carefully considered as the database did not
contain data from university hospitals that may employ in-
fectious disease experts or facilities with fewer than 200
beds. Furthermore, tracking transfers from or to other hos-
pitals could not be carried out. Therefore, the results might
not represent the daily practice of L-AMB administration
in Japan. Third, we could not evaluate AKI by assessing de-
creased urine volume and/or AKI biomarkers [22] as these
parameters could not be obtained from the database used
in this study. Lastly, due to the low number of subjects en-
rolled in this study, we could not evaluate the association
between adequate potassium supplementation and AKI oc-
currence using logistic regression analysis. Therefore, fur-
ther large-scale prospective studies that not only include Cr
levels, but also urine volume and/or AKI biomarkers, are
required to confirm the results obtained herein.
Conclusion
In this study, potassium supplementation was not associ-
ated with the occurrence of any stage of AKI in patients
with hypokalemia who were administered L-AMB.
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